Acorda again submits Fampridine-SR for U.S. approval

04/23/2009 | Reuters

Acorda Therapeutics resubmitted its multiple sclerosis drug Fampridine-SR for FDA approval a month after the agency rejected the application because of "format issues." Analysts expect the agency to accept the filing by late June and hand down a decision in February.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX